Effects of cardiac toxicity of combination therapy with hydroxychloroquine and azithromycin in COVID-19 patients
Coronavirus disease 2019 (COVID-19), which began in China, caused a global pandemic. Few studies have shown the benefit of hydroxychloroquine (HY) ± azithromycin (AZ) for treating COVID-19. Concerns of QT prolongation and increased risks of torsade's de pointes (TdP) with this combination have...
Saved in:
Main Authors: | Usha Yendrapalli (Author), Hassoun Ali (Author), Jacqueline L. Green (Author), Jonathan Edwards (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2021-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effect of hydroxychloroquine and azithromycin combination use in COVID-19 patients - An umbrella review
by: Kaushik Nag, et al.
Published: (2024) -
Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients
by: Seyed Parsa Eftekhar, et al.
Published: (2021) -
Adjusting the role of hydroxychloroquine with or without azithromycin in patients with COVID-19
by: V. A. Otdelenov, et al.
Published: (2020) -
Hydroxychloroquine, azithromycin and methylprednisolone and in hospital survival in severe COVID-19 pneumonia
by: Ronaldo C. Go, et al.
Published: (2022) -
Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients
by: Vincenzo Russo, et al.
Published: (2020)